Agents61
US equityPharmaceuticalsNYSE

AbbVie on the committee board

AbbVie is the post-Humira cliff test: immunology follow-ons, aesthetics, and a dividend that has to be earned again. Special-situation value belongs here more than mega-cap growth.

What isolated seats argue

Klarman/Tepper distress-to-normal vs. Fisher scuttlebutt on the new immunology stack. Debate: is the cliff already in the price?

Filing & structure checks

Humira erosion vs. Skyrizi/Rinvoq ramp, IRA negotiation, and aesthetics cyclicality. Patent language in the K, not the dividend yield.

AbbVie (ABBV)

Analyst · 16 seats

Independent briefs, then clerk assembly · 16 isolated prompts + 1 assembly pass · filing facts from SEC EDGAR (cached 7 days) — not investment advice, no buy button

Ask the desk

Preview seating. Paid desks are 16 / 29 / 48 / 61. $49 is Associate (29), not 61. Partners is the same 61 with more compute.

Isolated briefsAssembly1. Era Trend List2. Cycle Position + Thermometer3. Dual-Track Candidate Pool4. Investment Proposal5. Entry Plan6. Exit Discipline

Filing facts · SEC EDGAR

AbbVie Inc. · 10-K FY · FY2025 · ended 2025-12-31 · CIK 0001551152

Public filing · not a live quoteFY2025P/E · P/B · P/S cached model input
Revenue (FY)
$61.2B
Revenue YoY
+8.6%
Net income
$4.2B
Diluted EPS
$2.36
ROE
-129.2%
LT debt / equity
-19.73
P/E
108.1
P/B
P/S
7.39
Cached price
$255.00
Mkt cap (est.)
$452.1B

Filings from SEC companyfacts (us-gaap). P/B, P/S from cached price × diluted shares vs filings. Not a live quote. Not a live quote, not advice, not a buy button. Missing numbers stay blank; P/E shows n/m when diluted EPS ≤ 0.

Isolated briefs
16 seats · no peeking

Each master researches ABBV alone

Same file, different rules. Each brief states a view and why. Briefs are written in isolation so one loud narrative cannot drag the room. The clerk reads them only after they exist. Never “you should buy.” There is no buy button.

Cathie Wood
Disruptive Innovation Lead
Isolated
constructive

View

Constructive — the work is worth continuing, not an order. On ABBV, I care whether the decade capital flow still funds this vehicle — revenue YoY 8.6%, revenue $61.2B.

Why

Why: Horizon is 5+ years; reject 12-month price targets as the main frame. If the industry is not on the decade map, I pass without a speech. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Business dig: ABBV must still sit inside a funded decade theme — not a tourist ticker. On file: revenue $61.2B; revenue YoY 8.6%. Method: Horizon is 5+ years; reject 12-month price targets as the main frame. Second rule: Map the name to ARK-style platforms: AI, robotics, energy storage, multiomics, fintech rails. Variant view: the tape often prices the theme; this seat prices whether ABBV is the vehicle. Underwrite frame: Worth further homework.

Risks

Main risk: the era is right and the vehicle is wrong — or the era has already been bid.

Looks at

revenue CAGR vs category S-curve

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: linear legacy business dressed up as disruption.

Philippe Laffont
Tech Commercialization Validator
Isolated
constructive

View

Constructive — the work is worth continuing, not an order. On ABBV, I care whether the decade capital flow still funds this vehicle — revenue YoY 8.6%, revenue $61.2B.

Why

Why: A trend is only investable once it hits a commercialization inflection: revenue, not demos. If the industry is not on the decade map, I pass without a speech. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Business dig: ABBV must still sit inside a funded decade theme — not a tourist ticker. On file: revenue $61.2B; revenue YoY 8.6%. Method: A trend is only investable once it hits a commercialization inflection: revenue, not demos. Second rule: Demand proof of unit economics: contribution margin, payback, net retention. Variant view: the tape often prices the theme; this seat prices whether ABBV is the vehicle. Underwrite frame: Worth further homework.

Risks

Main risk: the era is right and the vehicle is wrong — or the era has already been bid.

Looks at

YoY revenue inflection

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: beautiful tech, no buyer with a budget.

Ray Dalio
Debt Cycle Architect
Isolated
cautious

View

Cautious — the file is open, the bar is not cleared. ABBV sits on the thermometer before any multiple debate — Late Expansion at 62.

Why

Why: cycle first. The short-term debt cycle is hot; long-term debt is still high. This is not crisis pricing. A hot reading is not a ticket. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Regime first: Late Expansion, thermometer 62. The short-term debt cycle is hot; long-term debt is still high. This is not crisis pricing. On ABBV: On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. I will not time an entry from this chair. I will say whether the print smells mid-cycle or peak. Underwrite frame: Worth further homework.

Risks

Main risk: treating a regime note as a timing ticket.

Looks at

policy rate vs inflation

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: equity thesis that only works if a late-cycle credit boom never ends.

Howard Marks
Market Pendulum Assessor
Isolated
cautious

View

Cautious — the file is open, the bar is not cleared. ABBV sits on the thermometer before any multiple debate — Late Expansion at 62.

Why

Why: cycle first. The short-term debt cycle is hot; long-term debt is still high. This is not crisis pricing. A hot reading is not a ticket. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Regime first: Late Expansion, thermometer 62. The short-term debt cycle is hot; long-term debt is still high. This is not crisis pricing. On ABBV: On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. I will not time an entry from this chair. I will say whether the print smells mid-cycle or peak. Underwrite frame: Worth further homework.

Risks

Main risk: treating a regime note as a timing ticket.

Looks at

credit spreads vs history

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: priced for perfection in a risk-on pendulum extreme.

John Templeton
Sentiment Extremes Detector
Isolated
cautious

View

Cautious — the file is open, the bar is not cleared. ABBV sits on the thermometer before any multiple debate — Late Expansion at 62.

Why

Why: cycle first. The short-term debt cycle is hot; long-term debt is still high. This is not crisis pricing. A hot reading is not a ticket. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Regime first: Late Expansion, thermometer 62. The short-term debt cycle is hot; long-term debt is still high. This is not crisis pricing. On ABBV: On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. I will not time an entry from this chair. I will say whether the print smells mid-cycle or peak. Underwrite frame: Worth further homework.

Risks

Main risk: treating a regime note as a timing ticket.

Looks at

drawdown from peak

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: priced as if nothing bad can happen.

Benjamin Graham
Margin of Safety Guardian
Isolated
skeptical

View

Skeptical — the burden of proof is on the bull case. Owner test on ABBV: P/E 108.1, P/B not on file, ROE -129.2%, net income $4.2B.

Why

Why: Teacherly, quantitative, unsentimental. I want a business I would own in full. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Owner earnings lens on ABBV. Teacherly, quantitative, unsentimental. Hard rule: Margin of safety: pay well below a conservative appraisal of intrinsic value (classically ~2/3). Numbers on file: P/E 108.1; P/B not on file; ROE -129.2%; net income $4.2B; revenue YoY 8.6%. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. A low multiple that needs a hero story is not a margin of safety. A rich multiple with durable ROE can still be a business — but then price is the risk. Underwrite frame: Pass for now.

Risks

Main risk: a multiple that looks cheap because earnings are peak, or a quality story that needs the multiple to re-rate.

Looks at

P/B

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: price > conservative value with no margin.

Warren Buffett
Moat & Management Final Review
Isolated
skeptical

View

Skeptical — the burden of proof is on the bull case. Owner test on ABBV: P/E 108.1, P/B not on file, ROE -129.2%, net income $4.2B.

Why

Why: Plain Midwest English, folksy metaphors, long-horizon. I want a business I would own in full. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Owner earnings lens on ABBV. Plain Midwest English, folksy metaphors, long-horizon. Hard rule: Circle of competence: if the business cannot be explained simply, pass. Numbers on file: P/E 108.1; P/B not on file; ROE -129.2%; net income $4.2B; revenue YoY 8.6%. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. A low multiple that needs a hero story is not a margin of safety. A rich multiple with durable ROE can still be a business — but then price is the risk. Underwrite frame: Pass for now.

Risks

Main risk: a multiple that looks cheap because earnings are peak, or a quality story that needs the multiple to re-rate.

Looks at

ROIC / ROE durability

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: no durable advantage.

Seth Klarman
Distressed & Special Situations
Isolated
skeptical

View

Skeptical — the burden of proof is on the bull case. Owner test on ABBV: P/E 108.1, P/B not on file, ROE -129.2%, net income $4.2B.

Why

Why: Cautious, cash-heavy, academic-practitioner. I want a business I would own in full. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Owner earnings lens on ABBV. Cautious, cash-heavy, academic-practitioner. Hard rule: Margin of safety is a philosophy, not a slogan — downside first. Numbers on file: P/E 108.1; P/B not on file; ROE -129.2%; net income $4.2B; revenue YoY 8.6%. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. A low multiple that needs a hero story is not a margin of safety. A rich multiple with durable ROE can still be a business — but then price is the risk. Underwrite frame: Pass for now.

Risks

Main risk: a multiple that looks cheap because earnings are peak, or a quality story that needs the multiple to re-rate.

Looks at

downside to liquidation or conservative FCF

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: priced as a quality compounder with no discount.

Duan Yongping
Business Model Clarity Checker
Isolated
skeptical

View

Skeptical — the burden of proof is on the bull case. Owner test on ABBV: P/E 108.1, P/B not on file, ROE -129.2%, net income $4.2B.

Why

Why: Plain Chinese-internet elder-brother tone: 本分, 买股票就是买公司. I want a business I would own in full. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Owner earnings lens on ABBV. Plain Chinese-internet elder-brother tone: 本分, 买股票就是买公司. Hard rule: Buying a stock is buying a piece of a company — if you would not buy the whole business, pass. Numbers on file: P/E 108.1; P/B not on file; ROE -129.2%; net income $4.2B; revenue YoY 8.6%. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. A low multiple that needs a hero story is not a margin of safety. A rich multiple with durable ROE can still be a business — but then price is the risk. Underwrite frame: Pass for now.

Risks

Main risk: a multiple that looks cheap because earnings are peak, or a quality story that needs the multiple to re-rate.

Looks at

business model in one sentence

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: cannot explain how the company makes money without jargon.

Peter Lynch
Ten-Bagger Hunter
Isolated
constructive

View

Constructive — the work is worth continuing, not an order. Classify ABBV before cheering growth. revenue YoY 8.6%. P/E 108.1.

Why

Why: Six-category company classification system.. Unclassified growth is a narrative. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Classify before multiple. Six-category company classification system.. revenue YoY 8.6%. P/E 108.1. revenue $61.2B. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. Fast growth with no category is how you buy a story. Stalwart growth with a broken category is how you overstay. Underwrite frame: Worth further homework.

Risks

Main risk: mis-classification — a cyclical labeled a compounder.

Looks at

EPS growth

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: story is complicated or constantly changing.

Joel Greenblatt
Magic Formula + Special Situations
Isolated
constructive

View

Constructive — the work is worth continuing, not an order. Classify ABBV before cheering growth. revenue YoY 8.6%. P/E 108.1.

Why

Why: Author of The Little Book That Beats the Market.. Unclassified growth is a narrative. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Classify before multiple. Author of The Little Book That Beats the Market.. revenue YoY 8.6%. P/E 108.1. revenue $61.2B. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. Fast growth with no category is how you buy a story. Stalwart growth with a broken category is how you overstay. Underwrite frame: Worth further homework.

Risks

Main risk: mis-classification — a cyclical labeled a compounder.

Looks at

EBIT/EV

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: low ROC dressed up as growth.

David Einhorn
Financial Statement Quality Inquisitor
Isolated
skeptical

View

Skeptical — the burden of proof is on the bull case. Invert ABBV first. What has to be false for the bull to die?

Why

Why: kill-shot seat. Red team only: interrogate, do not pitch a long Footnotes beat stories. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Invert ABBV. Red team only: interrogate, do not pitch a long. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. Name what must be true for the bull: earnings quality, leverage (-19.73), and whether footnotes hide the cycle. If I cannot name the kill path, I am not doing the job. Underwrite frame: Pass for now.

Risks

Main risk: the fraud/cycle path is in the footnotes and the bull case ignores it.

Looks at

receivables vs revenue

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: earnings quality fails even if the narrative is popular.

Michael Burry
Extreme Contrarian: Hidden Assumptions
Isolated
skeptical

View

Skeptical — the burden of proof is on the bull case. Invert ABBV first. What has to be false for the bull to die?

Why

Why: kill-shot seat. Red team: dismantle the valuation model's hidden assumptions Footnotes beat stories. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Invert ABBV. Red team: dismantle the valuation model's hidden assumptions. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. Name what must be true for the bull: earnings quality, leverage (-19.73), and whether footnotes hide the cycle. If I cannot name the kill path, I am not doing the job. Underwrite frame: Pass for now.

Risks

Main risk: the fraud/cycle path is in the footnotes and the bull case ignores it.

Looks at

embedded growth rate in the multiple

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: terminal growth or multiple assumes a world that the footnotes contradict.

Charlie Munger
Inversion Thinking Arbiter
Isolated
skeptical

View

Skeptical — the burden of proof is on the bull case. Invert ABBV first. What has to be false for the bull to die?

Why

Why: kill-shot seat. Invert: how would this thesis get killed? List the kill-shots before the romance Footnotes beat stories. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. Invert ABBV. Invert: how would this thesis get killed? List the kill-shots before the romance. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. Name what must be true for the bull: earnings quality, leverage (-19.73), and whether footnotes hide the cycle. If I cannot name the kill path, I am not doing the job. Underwrite frame: Pass for now.

Risks

Main risk: the fraud/cycle path is in the footnotes and the bull case ignores it.

Looks at

incentive structure

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: the idea only works if several things go right at once without a margin.

William O'Neil
CANSLIM Entry Point
Isolated
constructive

View

Constructive — the work is worth continuing, not an order. No trigger, no implied entry on ABBV — quality seats do not move this pencil.

Why

Why: without a stage/breakout/turtle trigger, a good business is still not an entry.

Analysis

Question: “Research ABBV as a US-listed name.”. Trigger or nothing. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. Stage / breakout / turtle — pick the method this seat uses. A constructive quality seat elsewhere does not create an entry here. Underwrite frame: Worth further homework.

Risks

Main risk: entering because the committee liked the business.

Looks at

quarterly EPS acceleration

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: laggard in a leading group.

Ed Thorp
Kelly Criterion Position Sizing
Isolated
skeptical

View

Skeptical — the burden of proof is on the bull case. ABBV is a distribution. P/E 108.1; P/B not on file. Thin sample → smaller size.

Why

Why: if edge is not measurable, Kelly ceiling collapses. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

Analysis

Question: “Research ABBV as a US-listed name.”. ABBV is a return distribution, not a feeling. On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached. P/E 108.1; P/B not on file. If sample is thin or correlations hid risk, size shrinks. Kelly is a ceiling. Underwrite frame: Pass for now.

Risks

Main risk: overfitting a short sample or sizing as if variance were known.

Looks at

whether a statistical edge is even claimed

On file: 10-K FY FY2025; revenue $61.2B; revenue YoY 8.6%; net income $4.2B; ROE -129.2%; LT debt/equity -19.73; P/E 108.1; P/S 7.4; price $255.00 cached.

This seat flips if: no quantified edge.

Committee tables and charts

Counted from isolated briefs. Ratios are filings or cached model input — not a live quote, not a rating, not a buy button.

Stance mix

16
  • constructive5
  • cautious3
  • skeptical8
  • inconclusive0

Cycle scenario fan (%)

0255075100BoomRecoveryStagflationRecession

Valuation and filings (P/E, P/B, …)

MetricValueNote
P/E108.1P/B, P/S from cached price × diluted shares vs filings. Not a live quote.
P/BP/B, P/S from cached price × diluted shares vs filings. Not a live quote.
P/S7.39
ROE-129.2%
LT debt / equity-19.73
Revenue (FY)$61.2B
Revenue YoY+8.6%
Net income$4.2B
Diluted EPS$2.36
Clerk assembly

Then the briefs are stacked — not averaged

constructive
5
cautious
3
skeptical
8
inconclusive
0

Where they agree

  • The clerk stacked isolated notes on: “Research ABBV as a US-listed name.”. Masters did not see each other’s drafts.
  • Quality seats treat “would I own the whole company?” as the filter, not next-quarter beat.

Where they split

  • Value/quality seats ask whether it is a business worth owning; growth seats ask whether the story is still underappreciated. Those are different tests.
  • Debate seats write kill-shots before any clerk summary. They are not asked to “meet in the middle.”
  • Constructive and skeptical briefs both survived isolation — the clerk does not erase the split.

Analyst covers the working 16. Associate adds 13 red-team, cycle, and timing seats (29 total). Exit stays on Committee.

Assembly is a second isolated pass over the briefs. Masters did not read each other. Research simulation — not advice, not a buy button.

Associate unlocks 29 independent seats (29 isolated prompts + 1 assembly pass).

See Associate

Split after isolation

Counted from independent briefs only — not a vote, not a recommendation.

31%
19%
50%
5 constructive 3 cautious / inconclusive 8 skeptical
Step 1 · Where does capital flow over the next decade?

Era Trend List

ABBV is mapped against this week’s trend board by the unlocked trend seats. Strength is a committee score, not a price forecast.

AI infrastructure is still in a capex peakStrength 8/10SemiconductorsCloudPower
Digital ads and new consumption have not fully penetratedStrength 7/10InternetConsumer
Decade-scale platforms remain a long-run raceStrength 7/10EVSoftwarePayments
High-return cash compounders are scarcer at higher ratesStrength 6/10Consumer staplesHealthcareExchanges
The trend is diffusing into EM; US-listed ADRs are the windowStrength 5/10EM internetEnergy transition
Step 2 · Where are we in the cycle?

Cycle Position Report

62Late Expansion
Boom
18%
Recovery
22%
Stagflation
27%
Recession
33%
  • Dalio: The short-term debt cycle is hot; long-term debt is still high. This is not crisis pricing.
  • Marks: The pendulum has left midpoint toward optimism, but not yet euphoria.
  • Templeton: There is not enough pessimism to call this a maximum-pessimism buy.
Step 3 · What to buy — why this ticker is in the pool, or not

Why this name (dual track)

Value / Quality track

Benjamin Graham

ABBV: screened alone against Margin of Safety Guardian.

Warren Buffett

ABBV: screened alone against Moat & Management Final Review.

Seth Klarman

ABBV: screened alone against Distressed & Special Situations.

Duan Yongping

ABBV: screened alone against Business Model Clarity Checker.

Growth / Opportunity track

Peter Lynch

ABBV: screened alone against Ten-Bagger Hunter.

Joel Greenblatt

ABBV: screened alone against Magic Formula + Special Situations.

Step 4 · Bull case vs. red-team interrogation — after isolation

Investment Proposal

Debate starts only after independent briefs exist. Red team still does not see a shared draft.

Red-team interrogation

David Einhorn
Earnings quality and accounting traps
Michael Burry
Extreme inversion: what assumptions hide in the model

Charlie MungerDebate chair · inversion: the best way to kill this thesis

Warren BuffettFinal review · 10-year hold test

Full transcript, risk list, and sizing stay on higher seats.

Unlock more seats
Step 5 · When to buy, and how much

Entry Plan

William O'Neil
CANSLIM buy point: cup-with-handle breakout + market-follow-through
Step 6 · When to sell

Exit Discipline

Exit desk (Livermore, Darvas, Bogle accountability) is locked on Analyst.

Unlocks on Committee or Partners (61). Empty seats stay empty — we do not ghost-fill them.

Compare plans

Quant Risk Control

Backtest + sizing + risk budget. Verify every intuition — after the isolated briefs, not instead of them.

Ed Thorp

Agents61 is a research simulation and educational tool. Isolated views, splits, and assembly notes only. Not personalized advice. AI-generated.